Does Security Health Plan Cover Prolia (Denosumab)?

What Is Prolia and Why Does Coverage Matter?

Prolia (denosumab) is a fully human monoclonal antibody that inhibits RANK ligand, slowing osteoclast-mediated bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and it carries additional indications for men with osteoporosis, glucocorticoid-induced osteoporosis, and cancer-treatment-related bone loss. [1]

The drug's cost makes coverage decisions consequential. Without insurance, a single 60 mg prefilled syringe carries an AWP of roughly $2,100, $2,400, translating to an annual drug cost of $4,200, $4,800 before any dispensing or administration fees. That figure dwarfs a year's supply of generic alendronate, which runs under $100 at most pharmacies.

Coverage matters clinically, not just financially. The FREEDOM trial (N=7,868 to 36 months) showed denosumab reduced new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26, 0.41, P<0.001) and hip fractures by 40% (relative risk 0.60 to 95% CI 0.37, 0.97, P=0.04) compared with placebo in postmenopausal women with T-scores between -2.5 and -4.0. [2] Losing coverage mid-therapy is particularly dangerous because abrupt discontinuation of denosumab is associated with rebound vertebral fractures, sometimes multiple, within 12 to 18 months of the missed dose. [3]

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines state: "Denosumab is a preferred agent for patients who are intolerant of or unresponsive to oral bisphosphonates, or for whom adherence with oral therapy is problematic." [4] That clinical endorsement does not automatically translate to insurance approval, which is why understanding Security Health Plan's specific criteria is essential before prescribing or beginning therapy.

How Security Health Plan Classifies Prolia: Medical vs. Pharmacy Benefit

Security Health Plan, a Wisconsin-based insurer affiliated with Marshfield Clinic Health System, administers both commercial fully-insured plans and Medicare Advantage products. The benefit category Prolia falls under determines how it is billed, what your cost-sharing looks like, and which formulary rules apply.

For most Security Health Plan commercial members, Prolia is covered under the medical benefit when administered in a physician's office or outpatient infusion suite. Under the medical benefit, the drug is billed on a CMS-1500 or UB-04 claim using HCPCS code J0897 (injection, denosumab, 1 mg), with 60 units per dose. Your cost-sharing is calculated as a percentage of the allowed amount rather than a fixed copay, so coinsurance of 20 to 30% can still mean hundreds of dollars per injection.

Some Security Health Plan pharmacy plans include a specialty pharmacy tier where Prolia may be dispensed through a contracted specialty pharmacy and self-administered at home or in-office. Under a pharmacy benefit, you pay the specialty tier copay or coinsurance, which can range widely.

The 2023 IQVIA Institute report found that specialty drug list prices have risen an average of 4 to 7% annually over the preceding five years, making precise out-of-pocket forecasting difficult without checking the current plan year's formulary directly. [5] Security Health Plan publishes formularies on its website; you can also call the Member Services number on your insurance card and ask specifically whether J0897 is covered under your medical or pharmacy benefit and what your plan-year cost-sharing tier is.

Prior Authorization: What Security Health Plan Typically Requires

Prior authorization (PA) is required for Prolia on virtually all Security Health Plan commercial and Medicare Advantage plan types. The PA criteria are drawn from clinical-policy bulletins that Security Health Plan updates periodically. While the exact language changes year to year, the documentation a prescriber typically must submit includes the following.

Diagnosis confirmation. The claim must document osteoporosis (ICD-10 M81.0 for postmenopausal osteoporosis, or the applicable code for secondary osteoporosis). For Medicare Advantage members, bone mineral density (BMD) testing must meet Medicare's coverage criteria: a central DXA showing a T-score at or below -2.5, or a T-score at or below -1.0 in a patient who has already sustained a low-trauma (fragility) fracture. Medicare covers BMD testing every 24 months for eligible women, a schedule the USPSTF also endorses for women aged 65 and older. [6]

Step therapy with bisphosphonates. Security Health Plan, like most commercial payers, typically requires documented use of a bisphosphonate for at least 3, 12 consecutive months before approving Prolia. Alendronate 70 mg orally once weekly remains the most commonly required first-line agent because it is generic, inexpensive, and carries strong fracture-reduction evidence from the Fracture Intervention Trial (FIT, N=2,027), which showed a 47% relative risk reduction in hip fracture over 3 years (RR 0.53 to 95% CI 0.31, 0.90). [7]

Failure, intolerance, or contraindication. If a patient cannot complete the bisphosphonate trial, the prescriber must document the clinical reason. Acceptable exceptions generally include:

• Upper GI intolerance (esophagitis, Barrett's esophagus, active peptic ulcer disease)
• Severe renal impairment (eGFR <35 mL/min/1.73 m²), because bisphosphonates are contraindicated below this threshold [8]
• Prior atypical femoral fracture or osteonecrosis of the jaw attributed to bisphosphonate use
• Documented non-adherence despite adequate patient education

Prescriber specialty. Some Security Health Plan PA policies require the ordering clinician to be a licensed physician, physician assistant, or nurse practitioner with documented expertise in endocrinology, rheumatology, or primary care management of osteoporosis.

PA approval periods for Prolia are typically granted for 12 months (covering two doses), after which renewal documentation is required. The FDA label notes that if Prolia is discontinued, patients should transition to an alternative antiresorptive agent to prevent the rebound fracture risk described above. [1] Including a transition plan in the PA submission can strengthen the case.

Step Therapy and Alternative Agents

Step therapy policies exist because generic bisphosphonates are effective and cost far less than Prolia. Understanding the step therapy ladder helps patients and prescribers move through it efficiently, or document why it does not apply.

Alendronate 70 mg weekly is the usual first step. If that is not tolerated, risedronate 35 mg weekly or 150 mg monthly may satisfy the requirement. Zoledronic acid (Reclast) 5 mg IV annually is sometimes accepted as an alternative to oral bisphosphonates for patients with documented GI intolerance, though some payers treat it as a separate step. [9]

The HORIZON Key Fracture Trial (N=7,765 to 3 years) showed that zoledronic acid reduced vertebral fractures by 70% (RR 0.30 to 95% CI 0.24, 0.38, P<0.001) and hip fractures by 41% (RR 0.59 to 95% CI 0.42, 0.83, P=0.002) versus placebo, outcomes comparable to denosumab's FREEDOM results. [10] When a payer asks for bisphosphonate step therapy, this data explains why: the evidence base for first-line agents is strong.

Raloxifene 60 mg daily (a selective estrogen receptor modulator) and teriparatide 20 mcg daily subcutaneous injection are occasionally listed as intermediate steps or alternatives, though teriparatide carries its own high cost and PA requirements.

The HealthRX Clinical Coverage Framework for Prolia PA organizes the step-therapy and exception pathway into four sequential decision nodes:

1. Confirm T-score <-2.5 or fragility fracture with DXA report dated within 24 months.
2. Document bisphosphonate trial (agent name, dose, duration, dates of dispensing).
3. Record the specific reason for bisphosphonate failure or intolerance with objective clinical evidence (endoscopy report, renal function panel, radiology report for atypical fracture).
4. Attach the prescriber attestation letter citing AACE 2020 guidelines and the FREEDOM trial fracture-reduction data.

Submitting all four nodes in the initial PA package reduces the rate of first-pass denials and shortens the overall approval timeline.

Medicare Advantage Members: Additional Considerations

Security Health Plan offers Medicare Advantage plans (HMO and PPO variants) in Wisconsin. For Medicare Advantage members, Prolia coverage rules must be at least as generous as traditional Medicare's coverage criteria. Traditional Medicare covers Prolia under Part B (medical benefit) when administered by a provider, using HCPCS J0897, subject to a 20% coinsurance after the Part B deductible ($240 in 2024). [11]

Starting January 1, 2025, the Inflation Reduction Act caps Medicare Part D out-of-pocket drug costs at $2,000 per year, which may affect members whose plans cover Prolia under the pharmacy rather than medical benefit. The CMS finalized this cap in the 2025 Medicare Advantage and Part D final rule. [12]

Medicare Advantage plans may apply their own utilization management tools, including PA, step therapy, and quantity limits, as long as they do not restrict access below traditional Medicare's baseline. If a Medicare Advantage PA denial seems inconsistent with what traditional Medicare would cover, that is a strong basis for appeal.

What to Do If Security Health Plan Denies Prolia

Denials are not final. Federal and Wisconsin state law give you a structured path to challenge them.

Step 1: Internal appeal. You have the right to file an internal appeal within 60 days of receiving the denial notice (or longer under some plans). Submit a letter from your prescriber that addresses each denial reason point-by-point, includes the FREEDOM trial citation showing the fracture-reduction benefit, references the AACE 2020 guideline recommendation, and attaches any clinical records documenting bisphosphonate failure or contraindication.

Step 2: Expedited appeal. If your physician certifies that the standard appeal timeline would seriously jeopardize your health, you may request an expedited review. Security Health Plan must respond within 72 hours for urgent cases under CMS rules. [13]

Step 3: External Independent Review. If the internal appeal is denied, you have the right to request review by an Independent Review Organization (IRO). Wisconsin-regulated plans are subject to Wis. Stat. § 632.835, which requires IRO review for adverse benefit determinations. Medicare Advantage members have an additional right to appeal through the Medicare Appeals Council.

Step 4: State Insurance Commissioner. The Wisconsin Office of the Commissioner of Insurance (OCI) accepts complaints and can intervene when insurers fail to follow their own coverage criteria or applicable law.

The Endocrine Society's clinical practice guideline on osteoporosis pharmacotherapy notes that denosumab "should not be discontinued without a plan for subsequent antiresorptive therapy" because of the rebound fracture risk. [14] Including this safety language in an appeal letter reframes a coverage dispute as a patient-safety issue, which IROs weigh heavily.

Cost-Reduction Programs While Awaiting Coverage

Even when coverage is approved, cost-sharing can be substantial. Several programs can reduce your actual out-of-pocket expense.

Amgen SUPPORT Program. Amgen, Prolia's manufacturer, offers a co-pay assistance card for commercially insured patients that may reduce cost-sharing to as low as $0 per dose (subject to eligibility criteria and annual caps). Patients can enroll at 1-800-272-9376 or through the Amgen SUPPORT website. Note that this program is not available for patients with Medicare, Medicaid, or other government-funded coverage.

State Pharmaceutical Assistance Programs. Wisconsin does not currently operate a state-funded pharmaceutical assistance program specifically for Prolia, but the Wisconsin SeniorCare program provides drug coverage for low-income Medicare beneficiaries aged 65 and older and may cover some bone therapies. Contact the Wisconsin Department of Health Services for eligibility details.

340B Program. If your provider participates in the 340B drug-pricing program, they may be able to purchase Prolia at a significantly reduced acquisition cost, which can lower your out-of-pocket under a medical benefit copay structure.

Switching to an alternative for cost reasons. If cost remains prohibitive even with assistance, a conversation with your prescriber about zoledronic acid (often covered under Part B with only 20% coinsurance and one annual infusion) or ibandronate may be warranted. Each agent has a distinct fracture-reduction evidence base, and the choice should be individualized based on your T-score, renal function, GI history, and fracture risk as calculated by FRAX. [15]

Monitoring Requirements That May Affect Re-Authorization

Ongoing Prolia therapy requires periodic monitoring that payers use to confirm continued medical necessity. Security Health Plan's PA renewal submissions typically require:

• Serum calcium, phosphorus, and vitamin D (25-OH-D) levels checked before each dose, given denosumab's risk of hypocalcemia (reported in up to 9.6% of patients in some series) [16]
• Repeat DXA every 1 to 2 years to document treatment response or stability
• Documentation that no osteonecrosis of the jaw (ONJ) or atypical femoral fracture has occurred

The FDA label requires that patients receive adequate calcium and vitamin D supplementation during Prolia therapy: at least 1 to 000 mg of elemental calcium and 400 IU of vitamin D daily, with higher doses for patients who are deficient. [1] Documenting this supplementation in the medical record supports PA renewal.

AACE recommends that BMD be assessed by DXA at the lumbar spine and hip, with follow-up scans at 1 to 2 years after initiating therapy to evaluate response. [4] A T-score that has improved or stabilized is strong evidence for medical necessity at PA renewal.

Talking to Your Prescriber: What to Ask

Before submitting a Prolia PA through Security Health Plan, your prescriber's office should be able to answer these specific questions:

• Which benefit tier will Prolia be billed under (medical or pharmacy), and what is the applicable HCPCS code and cost-sharing percentage?
• Has the office checked the current Security Health Plan formulary and clinical policy bulletin for the plan year in which therapy would begin?
• Is the DXA report current (within 24 months), and does it document a T-score at or below -2.5 or a fragility fracture?
• What bisphosphonate did you previously try, at what dose and for how long, and does the medical record include pharmacy dispense records to prove the trial?
• Does the prescriber's office have experience submitting Prolia PAs to Security Health Plan, and does it have a dedicated PA coordinator?

Providers who have documented the answers to these questions before submitting the PA consistently achieve faster approvals. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) estimates that approximately 10.2 million Americans aged 50 and older have osteoporosis and another 43.4 million have low bone mass, making PA navigation for bone therapies a high-volume administrative task in most endocrinology and primary care practices. [17]

Security Health Plan Member Services: Contact Information

Security Health Plan Member Services can be reached at the phone number printed on your insurance card (typically 1-800-472-2363 for commercial members or the Medicare Advantage member line). When you call:

1. Ask for the Pharmacy or Medical Management department.
2. Request the current clinical policy bulletin for denosumab (Prolia).
3. Ask whether your specific plan requires PA, step therapy, or quantity limits.
4. Request the formulary tier and your plan-year cost-sharing for J0897.
5. Ask for the fax number to which your prescriber should submit the PA request.

Getting this information in writing (ask for it to be mailed or emailed) protects you during an appeal if the plan later denies a claim that a Member Services representative said would be covered.